Clinical Report: Exploring Radiogenomics and DNA Damage Response in PDAC
Overview
This review discusses the potential of radiogenomics and DNA damage response inhibitors in pancreatic ductal adenocarcinoma (PDAC).
Background
Pancreatic ductal adenocarcinoma (PDAC) is known for its poor prognosis and high radioresistance, complicating treatment with radiotherapy. Radiogenomics examines how genetic variations affect radiotherapy response.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
Radiogenomics studies how genetic variations influence radiotherapy response.
The radiosensitivity index (RSI) and genomic-adjusted radiation dose (GARD) are tools for personalized radiotherapy dosing.
PDAC is one of the most radioresistant cancers.
DNA damage response (DDR) inhibitors may sensitize PDAC to radiation.
KRAS inhibitors represent a novel approach for radiosensitization in PDAC.
Clinical Implications
Incorporating genetic profiling into treatment planning may improve radiotherapy in PDAC.
Conclusion
The integration of radiogenomics and targeted therapies requires further validation.
by Marie Nour Karam, Joseph Hajj, Christopher H. Crane, Paul Ramia, Fady Geara, Nadim Hamadeh, Jacob G. Scott, Stephen Grobmyer, Rachael Almond, Eileen M. O’Reilly, Carla Hajj
